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Induction of G2/M phase transition in mitotic
and meiotic cell cycles requires activation by
phosphorylation of the protein phosphatase
Cdc25. Although Cdc2/cyclin B and polo-like
kinase (PLK) can phosphorylate and activate
Cdc25 in vitro, phosphorylation by these two
kinases is insufficient to account for Cdc25
activation during M phase induction. Here we
demonstrate that p42 MAP kinase (MAPK), the
Xenopus ortholog of ERK2, is a major Cdc25
phosphorylating kinase in extracts of M phase-
arrested Xenopus eggs. In Xenopus oocytes,
p42 MAPK interacts with hypophosphorylated
Cdc25 before meiotic induction. During meiotic
induction, p42 MAPK phosphorylates Cdc25 at
T48, T138, and S205, increasing Cdc25’s phos-
phatase activity. In a mammalian cell line,
ERK1/2 interacts with Cdc25C in interphase
and phosphorylates Cdc25C at T48 in mitosis.
Inhibition of ERK activation partially inhibits
T48 phosphorylation, Cdc25C activation, and
mitotic induction. These findings demonstrate
that ERK-MAP kinases are directly involved in
activating Cdc25 during the G2/M transition.
INTRODUCTION
Induction of mitosis and meiosis in the eukaryotic cell
cycle requires the coordinated activation of multiple M
phase-inducing protein kinases. Central in this process
is activation of Cdc2/cyclin B, which results from dephos-
phorylation of Cdc2 by the protein phosphatase Cdc25.
For this rate-limiting event to occur, Cdc25 needs to be
activated in an initiation step prior to Cdc2 activation
and then is further activated in an amplification step afterCdc2 activation. Previous studies demonstrated that
Cdc2/cyclin B phosphorylates the N-terminal regulatory
domain of Cdc25 at specific S/T-P motifs, thereby in-
creasing Cdc25’s phosphatase activity (Izumi and Maller,
1993; Hoffman et al., 1993). These findings led to the
hypothesis that Cdc2 kinase forms a direct positive feed-
back loop with Cdc25, thereby amplifying Cdc25 activa-
tion. Previous studies also established that a polo-like ki-
nase (PLK), which is activated downstreamof Cdc2 kinase
(Karaiskou et al., 1998, 1999; Okano-Uchida et al., 2003),
binds the N-terminal regulatory domain of Cdc25 and
phosphorylates it at a D/E-X-S/T-Ø-X-D/E motif (Kumagai
and Dunphy, 1996; Nakajima et al., 2003; Toyoshima-
Morimoto et al., 2002). Since PLK interaction with Cdc25
is promoted by Cdc2-catalyzed phosphorylation of
Cdc25 (Elia et al., 2003a; Elia et al., 2003b; Sillje and
Nigg, 2003), PLK is likely to be also involved in the ampli-
fication step of Cdc25 activation (Glover et al., 1998).
However, Cdc2/cyclin B and PLK do not phosphorylate
recombinant Cdc25 at all sites that are phosphorylated
in M phase cell lysates (Kumagai and Dunphy, 1996;
Margolis et al., 2006). In addition, in interphase cell ly-
sates, phosphorylation of Cdc25 by both Cdc2/cyclin B
and PLK does not recapitulate the Cdc25 phosphorylation
and activation observed inMphase cell lysates (Karaiskou
et al., 1998). In the absence of Cdc2 activity, Cdc25 can
still be phosphorylated and activated by inhibiting okadaic
acid (OA)-sensitive phosphatases (Izumi et al., 1992).
These unexplained observations predict that one or multi-
ple additional kinases are involved in Cdc25 activation
during the G2/M transition.
To search for the putative additional kinase(s), we ana-
lyzed the Cdc25 phosphorylating activity in M phase-
arrested Xenopus egg extracts (MEE) by protein fraction-
ation. MEE is an excellent model system, as it contains
hyperphosphorylated and activated Cdc25, and incuba-
tion of recombinant Cdc25 with MEE recapitulates the M
phase-associated phosphorylation and activation of
Cdc25 (Izumi et al., 1992; Kumagai and Dunphy, 1992).
Thus, most, if not all, of the putative additional kinasesCell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc. 1119
involved in Cdc25 activation should be present in active
forms in MEE. By biochemical fractionation, we discov-
ered that p42 MAP kinases (MAPK), the Xenopus ortholog
of ERK2, accounts for a major portion of the Cdc25-phos-
phorylating activity in MEE, leading us to hypothesize that
ERK-MAP kinases are crucial components in the Cdc25
activating system. To test this hypothesis, we examined
phosphorylation and activation of Cdc25 by p42 MAPK
andmammalian ERKs both in vitro and duringM phase in-
duction. Our results not only demonstrate crucial involve-
ment of p42 MAPK in Cdc25 activation during meiotic
maturation of Xenopus oocytes but also show that ERK-
MAP kinases are involved in activating Cdc25C during mi-
totic induction of mammalian cells.
RESULTS
MEE Contains Novel Cdc25-Phosphorylating
Activities
To analyze the Cdc25-phosphorylating activity in MEE, we
initially determined the contribution of Cdc2 kinase and/or
XenopusPLKortholog1 (Plx1) to the totalCdc25-phosphor-
ylating activity by three independent approaches. MEEwas
prepared with the classic MPF extraction buffer (Wu and
Gerhart, 1980) that was supplemented with ATP-g-S and
theproteinphosphatase inhibitorOA, and1:4 to1:64diluted
MEE phosphorylatedGST-tagged Cdc25 (GST-Cdc25) in a
dose-dependent manner (Figure 1A). We observed that de-
pletion of Cdc2with p13-sepharose and Plx1 with anti-Plx1
antibodies from 1:10-dilutedMEE removed 90% of the his-
tone H1 kinase activity but <20% of the Cdc25-phosphory-
lating activity (Figure 1B). Partially purified Cdc2/cyclin B
from MEE containing 90% of the H1 kinase activity in
1:10-diluted MEE catalyzed 10% of the Cdc25 phosphory-
lation by the MEE sample (Figure 1C). Further, we fraction-
ated the40%ammoniumsulfate precipitate ofMEEbycon-
secutive gel filtration and Q-sepharose chromatography
and followed Cdc25-phosphorylating activity by a GST-
Cdc25 gel mobility shift assay. One broad peak of Cdc25-
phosphorylating activity was recovered (Figure 1D), indica-
tive of recovery ofmultipleCdc25-phosphorylating kinases.
Most importantly, the Q-sepharose chromatography sepa-
rated the Cdc25-phosphorylating activity into a minor
peak (QF) and amajor peak (QE1) (Figure 1E). Theminor ac-
tivity in QF coincided with most of the recovered H1 kinase
activity and could be depleted with the Cdc2 affinity resin
p13-sepharose, whereas the major activity in QE1 con-
tained little H1 kinase activity and could not be depleted
withp13-sepharose (Figure1F).Further,QE1contained little
Plx1-dependent Cdc25-phosphorylating activity (Fig-
ure S1). Together, these results indicate that Xenopus egg
extracts contain previously unrecognized Cdc25-phos-
phorylating kinases.
p42 MAPK Is One of the Novel Cdc25-
Phosphorylating Kinases in Xenopus Egg Extracts
To identify the novel Cdc25-phosphorylating kinases in
MEE, we fractionated QE1 further by consecutive sucrose1120 Cell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc.gradient sedimentation, hydroxyapatite chromatography,
Affi-Gel blue chromatography, and Superose 6 gel filtra-
tion and followed the Cdc25-phosphorylating activity by
the gel mobility assay. One peak of Cdc25-phosphorylat-
ing activity was recovered in each step, and the activity re-
covered in the last step coeluted with the 44 kDa standard
protein (Figure S2E). Since Xenopus p42 MAPK, the
Xenopus ortholog of ERK2, is both activated during Xeno-
pus oocyte maturation and important for Cdc2 activation
(Gotoh et al., 1995; Huang and Ferrell, 1996; Kosako
et al., 1994; Palmer and Nebreda, 2000; Shibuya et al.,
1992), we determined whether the purified activity from
QE1 was due to p42 MAPK. We observed that in the last
step of the purification, the Cdc25-phosphorylating activ-
ity copurified with the phosphorylating activity toward the
MAPK substratemyelin basic protein (MP) (Figure 2A). The
activity peak fractions contained a 42 kDa polypeptide
(Figure 2B, upper panel) that was recognized by anti-
MAPK antibodies (Figure 2B, lower panel). Moreover, im-
munodepletion of MAPK from the peak fractions removed
95% of the Cdc25-phosphorylating activity and 80% of
the MP-phosphorylating activity (Figure 2C). Immunode-
pletion of MAPK from unfractionated QE1 removed 50%
of the Cdc25-phosphorylating activity (Figure 2D). These
results demonstrate that the purified activity from QE1
was due to p42 MAPK. To evaluate the contribution of
p42 MAPK to the total Cdc25-phosphorylating activity in
MEE, we used both depletion and reconstitution ap-
proaches. Depletion of p42 MAPK from 1:10-diluted
MEE removed 50% of the MP-phosphorylating activity
and 60% of the Cdc25-phosphorylating activity (Fig-
ure 2E). Purified MAPK that contained 50% of the MP
phosphorylating activity in 1:10-diluted MEE phosphory-
lated GST-Cdc25 at 40% of the efficiency of the MEE
sample (Figure 2F). These results demonstrate that
MAPK is one of the major Cdc25-phosphorylating kinases
in MEE.
p42 MAPK Phosphorylates Cdc25 at T48, T138,
and S205 In Vitro
Cdc25 is known to be phosphorylated at five conserved
S/T-P motifs in Xenopus egg extracts (Izumi and Maller,
1993), including T48, T67, T138, S205, and S285 (Fig-
ure 3A). To identify the MAPK phosphorylation sites in
Cdc25, we first constructed five GST-tagged Cdc25 frag-
ments (F1–F5) that contained residues 9–129, 128–213,
251–353, 371–500, and 499–550 of Cdc25, respectively
(Figure S3A), and phosphorylated these fragments with
MEE, p42 MAPK, or Cdc2 kinase. MEE phosphorylated
F1, F2, and F3; Cdc2 kinase phosphorylated F2 and F3;
and MAPK phosphorylated F1 and F2 (Figure S3B). We
then mutated each of the potential phosphorylation sites
in F1, F2, and F3 and determined the effect on phosphor-
ylation by the relevant kinase(s). For Cdc2 kinase, the
T138V mutation completely eliminated phosphorylation
of F2, whereas the S205A mutation had little effect
(Figure 3B, left panel). Elimination of most of the F3 phos-
phorylation required both the S285A and T308Vmutations
Figure 1. MEE Contains Novel Cdc25-Phosphorylating Activities
(A) Quantification of GST-Cdc25 phosphorylation catalyzed by 1:4 to 1:64 diluted MEE.
(B) After 1:10-diluted MEE was mock treated or depleted of Cdc2, Plx1, or both, samples were immunoblotted for each of the indicated proteins and
assayed for phosphorylation of histone H1 or GST-Cdc25 by 32P incorporation.
(C)MEE that is 1:10-diluted and partially purifiedCdc2/cyclin B that contained 90%of the H1 kinase activity in theMEE sample were assayed for GST-
Cdc25 phosphorylation by 32P incorporation.
(D) Fractions from Ultrogel AcA 34 gel filtration of the 40% ammonium-sulfate precipitate of MEE were measured for inducing gel mobility shifts in the
full-length (100 kDa) and truncated (76 kDa) GST-Cdc25.
(E) Fractions from the consecutive Q-sepharose chromatography after the Ultrogel AcA 34 gel filtration were assayed for inducing the GST-Cdc25
shift.
(F) After QF and QE1 were absorbed with p13 or control sepharose, the starting material and unbound proteins were assayed for phosphorylating
histone H1 and inducing the GST-Cdc25 shift.(Figure 3B, right panel). These results indicate that Cdc2
kinase selectively phosphorylates T138, S285, and T308
in Cdc25. For p42 MAPK, the T48V mutation eliminated
80% of the phosphorylation of F1 (Figure 3C, left panel),
and the additional T67V mutation abolished the residualphosphorylation of F1 (data not shown). The T138V muta-
tion completely eliminated phosphorylation of a cleaved
product of but not of the full-length F2 (Figure 3C, middle
panel). The additional S205A mutation removed 70% of
the phosphorylation of the full-length F2 (Figure 3C, rightCell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc. 1121
Figure 2. Identification of p42 MAPK as
a Major Cdc25-Phosphorylating Kinase
in MEE
(A) Indicated fractions from the last step of the
consecutive chromatography of QE1, Super-
ose 6 gel filtration, were quantified for phos-
phorylation of MP and GST-Cdc25.
(B) SDS-PAGE-separated proteins in the indi-
cated fractions from the Superose 6 gel filtra-
tion were stained with silver (upper panel) and
immunoblotted with anti-MAPK antibodies
(lower panel).
(C) Control or MAPK-depleted peak fractions of
the Cdc25-phosphorylating activity from the
Superose 6 gel filtration were quantified for
phosphorylation of MP and GST-Cdc25.
(D) Control or MAPK-depleted QE1 was quan-
tified for relative phosphorylation of GST-
Cdc25.
(E) Control orMAPK-depleted 1:10 dilutedMEE
was quantified for relative phosphorylation of
MP and GST-Cdc25.
(F) MEE that is 1:10-diluted and purified MAPK
from QE1 that contained 50% of the MB phos-
phorylating activity in the MEE sample were
quantified for relative phosphorylation of MP
and GST-Cdc25.panel). These results indicate that MAPK mainly phos-
phorylates T48, T138, and S205 in Cdc25. In support of
this conclusion, MAPK readily phosphorylated the 9–205
but not the 204–550 fragment of Cdc25 (Figure S3C).
The single (T48V) and triple (T48V, T138V, and S205A) mu-
tations of the full-length Cdc25 reduced the MAPK-cata-
lyzed phosphorylation of Cdc25 by 50% and 80%–90%,
respectively (Figure 3D). Moreover, antibodies that specif-
ically recognize T48-phosphorylated Cdc25 (Figures S4A
and S4B) preferentially detected GST-Cdc25 that had
been phosphorylated by MAPK (Figure 3E). Depletion of
MAPK, but not Cdc2 and Plx1, from MEE greatly reduced1122 Cell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc.the T48 phosphorylation (Figure 3F). Consistent with Cdc2
and MAPK phosphorylating different sites in Cdc25,
MAPK and Cdc2 kinase phosphorylated different cleav-
age products of GST-Cdc25 (Figure S3D) and produced
different two-dimensional phosphopeptide maps from
GST-Cdc25 (Figure S3E).
p42 MAPK Phosphorylates Cdc25 at T48 and T138
in Xenopus Oocytes
To determine whether p42 MAPK phosphorylates Cdc25
in Xenopus oocytes, we first examined whether MAPK
can phosphorylate Cdc25 at T48 and T138 in the absence
Figure 3. Identification of Three In Vitro MAPK Phosphorylation Sites in Cdc25
(A) Sequence alignment of the N-terminal regulatory domains of Xenopus Cdc25 and human Cdc25C with five conserved T/S-P motifs highlighted
in red.
(B) Immunoblots (IB) and phosphorylation (32P) of wild-type and the indicated mutant forms of F2 and F3 by semirecombinant Cdc2/cyclin B.
(C) Immunoblots (IB) and phosphorylation (32P) of wild-type and the indicated mutant forms of F1 and F2 by activated recombinant MAPK. Asterisks
and bar symbols indicate the full-length and truncated substrates, respectively.
(D) Immunoblots (IB) and phosphorylation (32P) of wild-type and the indicated mutant forms of GST-Cdc25 by activated recombinant MAPK.
(E) Immunoblots of GST-Cdc25 that was phosphorylated to a similar extent by Cdc2 kinase, MAPK, and Plx1 with anti-pT48 antibodies.
(F) Immunoblots of GST-Cdc25 that was phosphorylated by 1:4-dilutedMEE that wasmock treated or depleted of Cdc2 plus Plx1 orMAPK alone with
anti-GST or anti-pT48 antibodies.of Cdc2 activation. To this end, Xenopus oocytes were in-
jected with a constitutively activated MEK1 (CA-MEK1)
plus either Wee1 or a control molecule, Xp95 (Che et al.,
1999), and activation of MAPK, phosphorylation of
Cdc25, and dephosphorylation of Cdc2 were followed
by immunoblotting. Both coinjections synchronously in-
duced MAPK activation and phosphorylation of T48 and
T138 within 2.5 hr in the absence of Cdc2 dephosphoryla-
tion (Figure 4A). The coinjected Wee1 was functional,
since it effectively blocked the eventual dephosphoryla-
tion of Cdc2 and the gel mobility shift of Cdc25 (Figure 4B)
as well as increases in histone H1 kinase activity and mi-
totic phosphoproteins recognized by MPM-2 monoclonalCantibody (Davis et al., 1983) (Figure S5A). Xenopus oo-
cytes were also injected with Xp95 or Wee1 alone and
then stimulated with progesterone. In Wee1-injected
oocytes, progesterone induced low levels of both MAPK
activation and Cdc25 phosphorylation at T48 in the
absence of Cdc2 activation (Figure S5B). These results
demonstrate that MAPK can phosphorylate Cdc25 inde-
pendently from Cdc2 activation. Next, we determined
whether MAPK phosphorylates Cdc25 in the presence
of Cdc2 activation. To this end, Xenopus oocytes were
injected with a constitutively activated Cdc2 (Cdc2-AF),
and MAPK activation, Cdc25 phosphorylation, and Cdc2
dephosphorylation were followed by immunoblotting.ell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc. 1123
Figure 4. p42 MAPK Phosphorylates Cdc25 at T48 and T138 in Xenopus Oocytes
(A) Extracts of oocytes collected at the indicated minutes after coinjection of CA-MEK1 andWee1 (MEK1/Wee1) or CA-MEK1 and Xp95 (MEK1/Con-
trol) were immunoblotted with antibodies that recognize phosphorylated/activated MAPK (pMAPK), phosphorylated/inactivated Cdc2 (pCdc2),
Cdc25, T48-phosphorylated Cdc25 (pT48-Cdc25), and T138-phosphorylated Cdc25 (pT138-Cdc25).
(B) Extracts of oocytes collected at the indicated hours after coinjection of CA-MEK1 and Xp95 mRNAs (MEK1/control) or CA-MEK1 and Wee1
mRNAs (MEK1/Wee1) were immunoblotted as described for (A).
(C) Extracts of oocytes collected at the indicated times after injection of Cdc2AF were immunoblotted as described for (A).
(D) Extracts of oocytes collected at the indicated times after injection of Cdc2AF and culture in the presence of UO124 or UO126 were immunoblotted
as described for (A). The asterisk indicates a nonspecific band recognized by anti-Cdc25 antibodies.Cdc2-AF concurrently induced activation of MAPK, phos-
phorylation of T48 and T138, the Cdc25 gel mobility shift,
and dephosphorylation of Cdc2 (Figure 4C). While inhibi-
tion of MAPK activation by the MEK1 inhibitor UO126 (Fa-
vata et al., 1998) did not affect the kinetics of Cdc2 de-
phosphorylation, this treatment significantly delayed and
greatly reduced the phosphorylation of T48 and T138 as
well as the Cdc25 gel mobility shift (Figure 4D). These re-
sults demonstrate that in the presence of activated Cdc2
kinase (and potentially other mitotic kinases), MAPK still
plays a significant role in Cdc25 phosphorylation.1124 Cell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc.p42 MAPK Interacts with Cdc25
Since MAPK typically interacts with its substrates (Biondi
and Nebreda, 2003; Pearson et al., 2001; Tanoue and
Nishida, 2003), we next examined whether MAPK inter-
acts with Cdc25. By GST pull-down assays, GST-Cdc25
interacted with maltose binding protein (MBP)-tagged
MAPK (MBP-MAPK) but not MBP alone (Figure 5A).
MBP-MAPK bound two C-terminal fragments of Cdc25
containing residues 375–550 and 204–550, respectively,
but not the three N-terminal fragments (Figure 5B). Further
deletion of the C-terminal 50 residues did not reduce
Figure 5. p42 MAPK Interacts with Hypophosphorylated Cdc25
(A) MBP and MBP-MAPK were incubated with GST-Cdc25, and proteins bound to GST-Cdc25 (right panel) were immunoblotted in parallel with 1/10
of the input protein (left panel) with anti-MBP antibodies.
(B) MBP-MAPK was incubated with GST or GST-tagged Cdc25 fragments, and proteins bound to each of the GST-Cdc25 products were immuno-
blotted with anti-MBP antibodies.
(C) Extracts of oocytes collected at 6 hr after injection with myc-tagged Cdc25 fragments were immunoprecipitated with anti-MAPK antibodies. The
MAPK immunocomplexes were immunoblotted in parallel with 1/10 of the input oocyte lysates with anti-myc and anti-MAPK antibodies (left panel).
The results and two deduced MAPK binding regions in Cdc25 are illustrated (right panel).
(D) After extracts of immature (I) or mature (M) oocyte extracts were immunoprecipitated with mouse IgG or an anti-Cdc25 monoclonal antibody,
immunocomplexes were immunoblotted with polyclonal anti-Cdc25 and anti-MAPK antibodies.
(E) After extracts of immature (I) and mature (M) oocytes that ectopically expressed the control (wt) or the T2S1 mutant form of myc-CI-Cdc25 were
immunoprecipitated with anti-MAPK antibodies, the input oocyte extracts, immunoprecipitated proteins, and supernatant after the immunoprecip-
itation were immunoblotted with anti-myc and anti-MAPK antibodies.GST-Cdc25 interaction with MBP-MAPK (data not
shown). These results show that the C-terminal catalytic
domain of Cdc25 contains a docking site for MAPK. By
coimmunoprecipitation approach, a myc epitope-tagged
catalytically inactive Cdc25 (myc-CI-Cdc25), which was
ectopically expressed in Xenopus oocytes, coimmuno-
precipitated with endogenous MAPK (data not shown).
Among the truncation products of myc-CI-Cdc25 tested,
the fragments N2 (9–287), N3 (9–375), C1 (375–550), and
C2 (204–550), but not the fragment N1 (9–213), coimmu-noprecipitated with MAPK (Figure 5C, left panel). How-
ever, the 213–375 fragment of Cdc25 did not coimmuno-
precipitate with MAPK (data not shown). These results
indicate that MAPK interacts with both the regulatory
and catalytic domains of Cdc25 in Xenopus oocytes
(Figure 5C, right panel) and strengthen the conclusion
that Cdc25 is a physiological substrate of MAPK.
Since MAPK interacts with latent p90rsk in immature
oocytes but not MAPK-phosphorylated p90rsk in mature
oocytes (Hsiao et al., 1994; Palmer et al., 1998), we furtherCell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc. 1125
1126 Cell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc.
determined whether phosphorylation of Cdc25 by MAPK
inhibits the Cdc25-MAPK interaction. Endogenous
Cdc25 coimmunoprecipitated with MAPK in immature
but not mature oocyte extracts (Figure 5D). Although
myc-CI-Cdc25 behaved similarly as endogenous Cdc25,
the T2S1 mutant form of myc-CI-Cdc25 coimmunopreci-
pitated with MAPK in both extracts (Figure 5E). These re-
sults indicate that phosphorylation of Cdc25 byMAPK has
negative effects on the Cdc25-MAPK interaction.
p42 MAPK Activates Cdc25 In Vitro
To determine whether phosphorylation of Cdc25 by
MAPK activates Cdc25 in vitro, wild-type and the T2S1
mutant form of His-Cdc25 were phosphorylated with acti-
vated recombinant MAPK, and phosphorylated and non-
phosphorylated proteins were measured in parallel for
the ability to dephosphorylate 3-O-methylfluorescein
phosphate (OMFP) (Gottlin et al., 1996). Phosphorylation
increased the phosphatase activity of the wild-type His-
Cdc25 several times but had much lesser effects on the
mutant His-Cdc25 (Figure 6A). Since MAPK also phos-
phorylates T67 and possibly other sites, the residual acti-
vation of themutant His-Cdc25 could be due to phosphor-
ylation of these sites. In addition to this direct approach,
selected preparations of GST-Cdc25 that had low basal
levels of the Cdc2-activating activity were phosphorylated
either with 1:4-diluted MEE that had been immunode-
pleted of endogenous Cdc25 or with an amount of purified
MAPK or Cdc2 kinase that contained similar levels of the
GST-Cdc25-phosphorylating activity. The phosphory-
lated Cdc25 by each kinase sample was then assayed in
parallel with nonphosphorylated Cdc25 for the ability to
activate latent Cdc2/cyclin B. As shown in Figure 6B, non-
phosphorylated GST-Cdc25 activated Cdc2/cyclin B in
a dose-dependent manner. While MEE-phosphorylated
GST-Cdc25 required a 16-fold dilution to match the activ-
ity of the nonphosphorylated GST-Cdc25, Cdc2- and
MAPK-phosphorylated GST-Cdc25 each reached the ac-
tivity of nonphosphorylated Cdc25 after a 4- to 8-fold dilu-
tion. These results indicate that both MAPK and Cdc2 ki-
nase partially activate Cdc25. We should note that
phosphorylation of GST-Cdc25 by both Cdc2 and MAPKCdid not further increase the endpoint dilution (data not
shown), indicating that additional factors are required for
complete activation of Cdc25.
Phosphorylation of Cdc25 by MAPK Enhances
Cdc25’s Maturation-Inducing Activity
To determine if MAPK is involved in Cdc25 activation in
Xenopus oocytes, we used multiple indirect approaches.
First, Xenopus oocytes were injected with CA-MEK1
plus the wild-type or T48V/T2S1 mutant form of myc-
Cdc25, and the effect of the MAPK-site mutations on the
combined ability of CA-MEK1 and Cdc25 to induce oo-
cyte maturation was examined. The T48V and the T2S1
mutations retarded Cdc25-induced oocyte maturation
by 2 and 2.5 hr, respectively (Figure 6C), indicating that
phosphorylation of Cdc25 by MAPK is positively involved
in MAPK-induced oocyte maturation. Second, Xenopus
oocytes were injected with the wild-type or one of the mu-
tant forms of myc-Cdc25 alone, and the effect of the
MAPK-site mutations on Cdc25’s ability to induce Xeno-
pus oocyte maturation was examined. The T48V and the
T2S1 mutations reduced the ability of Cdc25 to induce
oocyte maturation by 2- and 3-fold, respectively, and
delayed oocyte maturation by 1 and 2 hr, respectively
(Figure 6D), indicating that phosphorylation of Cdc25 by
MAPK is involved in Cdc2-induced oocyte maturation.
Further, oocyte maturation was induced by progesterone
stimulation or MEE injection, and the relationship between
phosphorylation of T48 and T138 and the dramatic gel
mobility shift of Cdc25, indicative of its M phase-associ-
ated activation, was examined. In progesterone-stimu-
lated oocytes, MAPK activation and T48/T138 phosphor-
ylation correlated with the Cdc25 gel mobility shift at the
onset of both meiosis I and II (Figure 6E). Delaying
MAPK activation by a brief treatment of oocytes with
UO126 before progesterone stimulation delayed both
T48/T138 phosphorylation and the Cdc25 gel mobility
shift (Figure S6A). When activation of MAPK was com-
pletely inhibited by injection of the MAPK phosphatase
XCL-100 (Lewis et al., 1995; Sohaskey and Ferrell, 2002)
or incubation with UO126, both T48/T138 phosphorylation
and the Cdc25 gel mobility shift were inhibited (Figures 6FFigure 6. p42 MAPK Activates Cdc25 In Vitro and In Vivo
(A) After wild-type or the T2S1 mutant form of His-Cdc25 was mock treated or phosphorylated by recombinant MAPK, the end products were
immunoblotted with anti-Cdc25 or anti-phospho-Cdc25 antibodies or assayed for dephosphorylation of OMFP. Error bars represent the standard
deviation from triplicate experiments.
(B) Latent Cdc2/cyclin B was treated with each of the indicated samples and then measured for phosphorylating histone H1.
(C) Oocytes were coinjected with CA-MEK1 and the wt or each of the indicated mutant forms of myc-Cdc25, and percentage of germinal vesicle
breakdown (GVBD) was scored after the indicated times. Oocyte extracts were made at the last timepoint and immunoblotted with anti-myc and
anti-HA antibodies.
(D) Oocytes were injectedwith wt or each of the indicatedmutant forms ofmyc-Cdc25, and percentage of GVBDwas scored after the indicated times.
Oocyte extracts were then made and immunoblotted with anti-myc antibodies.
(E) At the indicated times after progesterone stimulation, oocyte extracts were made and immunoblotted as described for Figure 4A.
(F) Oocytes were injected with Xp95 (control) or XCL-100 mRNA and stimulated with progesterone after 3 hr. Extracts of oocytes collected at the
indicated times after the progesterone stimulation were immunoblotted as described for Figure 4A.
(G) Oocytes that had been cultured in the presence of UO124 or UO126 for 1 hr were injected with MEE in the same culture medium, and extracts of
oocytes after the indicated hours were immunoblotted as described for Figure 4A.
(H) A schematic illustration of potential involvement of MAPK and another yet-to-be-identified Cdc25-phosphorylating kinase in Cdc25 activation
during progesterone-induced Xenopus oocyte maturation.ell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc. 1127
and S6B). In MEE-injected oocytes, MAPK activation and
T48/T138 phosphorylation also correlated with the Cdc25
gel mobility shift. Inhibition of MAPK activation by UO126
delayed and reduced both T48/T138 phosphorylation and
the Cdc25 gel mobility shift (Figure 6G). These results
strongly indicate that MAPK is involved in both the initia-
tion and amplification steps of Cdc25 activation during
Xenopus oocyte maturation.
Mammalian ERKs Interact with and Phosphorylate
Cdc25C in Somatic Cell Cycles
To determine if ERK-MAP kinases in mammalian somatic
cells are involved in regulating Cdc25C, the closest rela-
tive of Xenopus Cdc25 (Kumagai and Dunphy, 1992), we
first determined whether ERK2 interacts with Cdc25C
(hCdc25C) in a cell-cycle-dependent manner. By coim-
munoprecipitation, myc-hCdc25C ectopically expressed
in ovarian cancer A2780 cells interacted with ERK2
much more significantly in interphase cells than in mitoti-
cally arrested cells (Figure 7A). Similar results were ob-
tained when interaction between endogenous hCdc25C
and ERK2 was examined (Figure S7A). In contrast, inter-
action of ERK2 with hCdc25A or hCdc25B was not ob-
served (Figure S7B). Second, since hCdc25C is similarly
phosphorylated in mitosis as Xenopus Cdc25 in meiosis
(Strausfeld et al., 1994), we determined whether ERK2
phosphorylates hCdc25C at T48 in mitotic cells. Immuno-
blotting with T48 phosphospecific antibodies showed that
T48 phosphorylation is greatly elevated in mitotically ar-
rested relative to asynchronous A2780 cells (Figure 7B).
Immunodepletion of ERK1/2 from mitotic cell lysates
greatly reduced the T48 phosphorylating activity (Fig-
ure 7C). Examination of in vitro phosphorylation of GST-
tagged hCdc25A, B, and C showed that while p42
MAPK phosphorylated all three forms of hCdc25, the
phosphorylation was most robust with hCdc25C (Fig-
ure S7C). Third, we treated A2780 cells with the mitotic
blocker nocodazole, either alone or together with the
MEK inhibitor, UO126, and determined the effect of inhib-
iting ERK activation on T48 phosphorylation, gel mobility
shift of hCdc25C, and accumulation of MPM-2 reactive
phosphoproteins. UO126 reduced T48 phosphorylation
and the ratio of shifted to nonshifted hCdc25C by 50%
and decreased the level of MPM-2 reactive proteins by
30%–40% (Figures 7D–7F). These results concurred
with the previous observations demonstrating that inhibi-
tion of the ERK activation pathway by a variety of ap-
proaches, including mitogen starvation, siRNA-mediated
knockdown, or dominant-negative forms of essential
components in the ERK-activation pathway or specific
pharmacological inhibitors, causes a delay or partial inhi-
bition in mitotic entry (Foijer et al., 2005; Liu et al., 2004;
Roberts et al., 2002; Wright et al., 1999). These results
demonstrate that, although not specifically activated
during mitotic induction, mammalian ERKs are part of
the regulatory system that activates Cdc25C during mi-
totic induction. These results also imply that mammalian
cells probably possess a negative control mechanism1128 Cell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc.that inhibits Cdc25C phosphorylation by ERKs or alterna-
tively, a cell-cycle-regulated positive control mechanism
thatmakes ERKs efficiently phosphorylate Cdc25C during
the G2/M transition.
DISCUSSION
The molecular mechanism by which Cdc25 becomes ac-
tivated during M phase induction is one of the key unre-
solved problems in the eukaryotic cell-cycle control. For
the ultimate goal of resolving this problem, we utilized
Xenopus oocytes/eggs, model systems highly conducive
in studying the regulation of the G2/M transition biochem-
ical approaches, to search for previously unrecognized
kinases involved in Cdc25 activation, and sought confir-
mation of our findings in mammalian cells. Our results
show that in both systems, the ERK-MAPK kinase inter-
acts with the C-type Cdc25 (Cdc25C) in interphase and
phosphorylates and activates Cdc25C during M phase
induction. These findings have uncovered novel and im-
portant roles of ERK-MAP kinases in the M phase-
associated Cdc25C-activation system.
Full activation of Cdc25 during Xenopus oocyte matura-
tion requires both initiation and amplification steps (King
et al., 1994; Perdiguero and Nebreda, 2004). In principle,
kinases that are involved in the initiation step can be acti-
vated prior to Cdc2 activation, leading to a threshold level
of Cdc25 activity. Our results show that in progesterone-
stimulated Xenopus oocytes, p42 MAPK can be activated
at low levels prior to and independent of Cdc2 activation
(Figures 6E and S5B), as previously reported by Fisher
et al. (1999). These low levels of MAPK activation corre-
lated with low levels of Cdc25 phosphorylation (Fig-
ure S5B), and inhibiting MAPK activation inhibited
Cdc25 phosphorylation and activation (Figure 6F). Thus,
p42MAPK is an excellent candidate for one of the kinases
involved in initiating Cdc25 activation during Xenopus oo-
cyte maturation. Theoretically, the kinases that are in-
volved in the amplification step of Cdc25 activation can
both be activated by Cdc2 and activate Cdc25. Previous
studies demonstrated that activated Cdc2 kinase can in-
duce MAPK activation through both mRNA stabilization
and posttranslational modification of Mos (Castro et al.,
2001; Gotoh et al., 1991; Nebreda et al., 1995; Yue and
Ferrell, 2004). Our results show that MAPK activation is
critically involved in, although not absolutely required for,
Cdc2- or MEE-induced phosphorylation and activation of
Cdc25 (Figures 4D and 6G). Thus, p42MAPK is involved in
the amplification step of Cdc25 activation during Xenopus
oocyte maturation through a positive feedback loop con-
sisting of Cdc2,Mos,MEK,MAPK, andCdc25 (Figure 6H).
This positive feedback loop may explain the long-estab-
lished requirement of Cdc2 activation for robustMAPK ac-
tivation and the frequently observed synchrony of these
two events during progesterone-induced Xenopus oocyte
maturation (Ferrell, 1999; Gotoh and Nishida, 1995;
Kosako et al., 1994; Palmer and Nebreda, 2000). The
involvement of p42 MAPK in both the initiation and
Figure 7. Mammalian ERK2 Regulates Cdc25C in Somatic Cell Cycles
(A) After ERK2 was immunoprecipitated from interphase (I) or mitotic (M) extracts of A2780 cells that ectopically expressed myc-hCdc25C, input cell
lysates and the ERK2 immunoprecipitates were immunoblotted with anti-myc and anti-ERK antibodies.
(B) Interphase (I) and mitotic (M) extracts of A2780 cells were immunoblotted with anti-hCdc25C and anti-pT48-hCdc25C antibodies.
(C) Control or ERK1/2-immunodepleted lysates of mitotic A2780 cells were immunoblotted with antibodies for each of the indicated proteins (left
panel) or incubated with GST-hCdc25C, which was then immunoblotted with anti-pT48-hCdc25C and anti-GST antibodies (right panel).
(D) Crude lysates of A2780 cells that had been blocked with nocodazole either alone or together with U0126 for the indicated times were immuno-
blotted with antibodies for each of the indicated proteins. The ‘‘s’’ and ‘‘o’’ indicate nonshifted hCdc25C in interphase cells and shifted hCdc25C in
mitotic cells, respectively.
(E) Relative levels of the shifted and nonshifted Cdc25C in (D) were determined, and the ratio calculated was plotted.
(F) The MPM-2 reactive protein indicated by asterisk in (D) was quantified, and the normalized level was plotted.amplification steps of Cdc25 activation may also explain
the requirement of active MAPK for Mos-induced Cdc2
activation in Xenopus oocyte extracts in the absence of
protein synthesis (Huang and Ferrell, 1996), and the inhib-
itory effect of an N-terminally truncated p90rsk mutant
(named D2) that constitutively interacts with MAPK during
Xenopus oocytematuration (Gavin et al., 1999). In addition
to these direct roles of p42 MAPK in Cdc25 activation, the
MAPK phosphorylation site T138 in Xenopus Cdc25 is theCequivalent site in hCdc25C, whose phosphorylation
promotes PLK binding (Sillje and Nigg, 2003), raising the
possibility that ERK-MAP kinases also promote PLK-
dependent Cdc25 activation.
Having established the role of ERK-MAP kinases in the
Cdc25C-activation system, the next question is whether
MAPK is the only previously unrecognized kinase involved
in Cdc25C activation during M phase induction. Although
phosphorylation of Cdc25 by p42 MAPK accounts forell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Inc. 1129
Mos-induced Cdc2 activation in Xenopus oocyte extracts,
this finding does not explain how the phosphatase inhibi-
tor OA, which can bypass the requirement for progester-
one to induce Xenopus oocyte maturation (Rime et al.,
1990; Goris et al., 1989), induces Cdc2 activation without
activation of p42MAPK (Huang and Ferrell, 1996). In some
of the previous studies, inhibition of MAPK activation de-
lays, but does not block, progesterone-induced Xenopus
oocyte maturation (Dupre et al., 2002; Gross et al., 2000;
Fisher et al., 1999). In contrast to the natural stimulus pro-
gesterone, forced activation of MAPK does not always
induce Cdc2 activation in Xenopus oocytes or cell-free
systems (Shibuya et al., 1992).When it does, there is a sig-
nificant delay between robust MAPK activation and Cdc2
dephosphorylation (Figure 4B) (Huang and Ferrell, 1996;
Nebreda and Hunt, 1993). These multiple unexplained ob-
servations indicate that progesterone stimulation of Xeno-
pus oocytes activates at least one additional kinase that is
involved in Cdc25 activation. While sufficient activation of
p42 MAPK is probably able to initiate and amplify Cdc25
activation in cooperation with Cdc2 kinase and Plx1, com-
posite roles of p42 MAPK and this additional kinase may
cause quicker and more robust activation of Cdc25 and
Cdc2/cyclin B during Xenopus oocyte maturation (Fig-
ure 6H). In agreement with this hypothesis, our gel filtration
of MEE resulted in recovery of a much broader peak of
Cdc25-phosphorylating activity than can be accounted
for by p42 MAPK and/or Cdc2 activities (Figure 1D). De-
pletion of MAPK from QE1, which contained most of the
unaccounted-for Cdc25 phosphorylating activity in Xeno-
pus egg extracts, removed only 50% of the Cdc25-
phosphorylating activity (Figure 2D). The remaining activ-
ity can be stabilized by OA and thiophosphorylation and is
almost certainly due to a kinase complex of >200 kDa that
does not contain Cdc2, Plx1, or p42 MAPK (unpublished
data). Thus, we hypothesize that this yet-to-be-identified
Cdc25-phosphorylating activity in MEE represents the ad-
ditional kinase or one of the additional kinases involved in
Cdc25 activation during Xenopus oocyte maturation. The
presence of alternative regulators in Cdc25 activationmay
explain why studies by different investigators have yielded
differing results with respect to the requirement of MAPK
for Cdc2 activation during Xenopus oocyte maturation.
EXPERIMENTAL PROCEDURES
Preparation of Xenopus Egg Extracts, Immunoblotting, Kinase
Depletion, Kinase Activity Assays, and Chromatography
Preparation of Xenopus egg extracts, immunoblotting, p13-based
Cdc2 absorption, immunodepletion, and histone H1 kinase assay
were performed as previously described (He et al., 2005; Kuang and
Ashorn, 1993; Kuang et al., 1991). Antibodies used in this study and
protocols for the consecutive chromatography of Xenopus egg ex-
tracts are described in Supplemental Experimental Procedures.
Phosphorylation of Recombinant Cdc25 and GST Pull-Down
Preparation of GST-tagged Cdc25 or Cdc25 fragments and phosphor-
ylating kinases are described in Supplemental Experimental Proce-
dures. Measurement of phosphorylation of these proteins by 32P incor-
poration was carried out by incubation of 2.0 mg of GST-Cdc25 bound1130 Cell 128, 1119–1132, March 23, 2007 ª2007 Elsevier Into 5 ml of glutathione agarose (Sigma-Aldrich) with 15 ml of the kinase
sample in EB (80 mM sodium b-glycerol phosphate, 20 mM EGTA,
and 15 mM MgCl2) and 1 mM DTT supplemented with 0.2 mCi/ml
[g -32P]-ATP, 0.2 mM ATP, and 1 mM cAMP-dependent protein kinase
inhibitor (Sigma) at room temperature for 30 min. After the beads were
washed as done for immunoprecipitation, bound proteins were eluted
with SDS-PAGE sample buffer and separated by SDS-PAGE. The 32P
incorporation into GST-Cdc25 was revealed by autoradiography and
quantified by scintillation counting of dissected bands from dried
gels. GST-Cdc25 gel mobility shift assay was carried out by incubation
of MEE or chromatography fractions with 0.2–0.5 mg of GST-Cdc25 at
22C for 45 min in a final volume of 50 ml containing 20 mM NaF, 2 mM
ATP, 5 mM DTT, and 1.5 mM OA followed by immunoblotting of end
products with anti-Cdc25 antibodies.
For GST pull down, 5 mg of GST-tagged proteins were affinity ab-
sorbed onto 15 ml glutathione agarose preblocked with 5% milk at
4C for 1 hr and equilibrated in TBS (150 mM NaCl in 50 mM Tris-
HCl [pH 7.4]). After incubation at 4C for 2 hr with 100 ng of MBP-
tagged proteins dissolved in 50 ml TBS, beads were washed three
times with 50 mM Tris-HCl (pH 8.0), 500 mM NaCl, 0.1 mM EDTA,
0.1 mM EGTA, 0.5% Triton X-100, 0.5% Tween-20, and 1 mM DTT,
and eluted proteins were immunoblotted with anti-MBP antibodies.
Cdc25 Phosphatase Activity Assays
One-half micrograms of His-Cdc25 immobilized onto 5 ml of Ni-NTA
beads was mock treated or phosphorylated by recombinant MAPK
and washed. Its phosphatase activity was measured by incubation
with 250 ml of 0.5 M 3-O-methylfluorescein phosphate (OMFP) in the
reactive buffer containing 100 mM Tris-HCl (pH 8.2), 40 mM NaCl,
1 mMDTT, 10 mM glutathione, and 20% glycerol or the reaction buffer
alone at 37C for 15 min followed by measurement of absorbance at
477 nm (Gottlin et al., 1996). GST-Cdc25 was mock treated or phos-
phorylated to similar extents by 1:4-diluted MEE or partially purified
Cdc2/cyclin B from QF or purified MAPK from QE1, and the end
products were measured for Cdc2-activating activity as described in
Supplemental Experimental Procedures.
Injection and Maturation of Xenopus Oocytes
Stage VI Xenopus oocytes were obtained, microinjected, matured with
progesterone (Sigma), observed for GVBD, and extracted as previ-
ously described (Che et al., 1999). The MEK1 inhibitor U0126 and its
negative control analog U0124 (Calbiochem) were added to cultures
of stage VI oocytes at 50 mM. RNAs for oocyte injection were produced
by in vitro transcription of the linearized plasmids described in Supple-
mental Experimental Procedures using mMESSAGE SP6 Large Scale
In Vitro Transcription kit for Capped RNAs (Ambion) and purified by
LiCl precipitation.
Cell Culture, cDNA Transfection, Preparation of Cell Lysates,
and Immunoprecipitation
Ovarian cancer A2780 cells were cultured in RPMI 1640 medium
(Mediatech) that was supplemented with 2 mM L-glutamine and
10% fetal bovine serum (Atlanta Biologicals) and transfected with
8 mg cDNA/60 mm dish using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer instruction. Nocodazole was added to the cell-
culture medium at 400 ng/ml for 18 hr, and mitotically arrested cells
were selectively detached by manual tapping of culture dishes. Cell
lysates were prepared, immunoblotted, and immunoprecipitated as
previously described (He et al., 2005). Signals on immunoblots were
semiquantified with NIH image 1.62 software as previously described
(Wu et al., 2001).
Supplemental Data
Supplemental Data include seven figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be
found with this article online at http://www.cell.com/cgi/content/full/
128/6/1119/DC1/.c.
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